Facebook Page Lands Drugmaker In Hot Water With FDA

Law360, New York (March 12, 2014, 6:08 PM EDT) -- The U.S. Food and Drug Administration on Wednesday published a rare rebuke to a drugmaker over improper promotion on social media, chastising Switzerland-based IBSA Institut Biochimique SA over a Facebook page that allegedly didn’t disclose any risks for a drug that has a black box warning.

In its so-called untitled letter, which represents a relatively mild form of discipline, the FDA accused IBSA of creating a Facebook page for hypothyroidism drug Tirosint that failed to mention anything about potential side effects.

A screen grab provided by...
To view the full article, register now.